MedTrace Logo

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

NCT04458259 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2025-08-28

No results posted yet for this study

Summary

A First-in-Human Pharmacokinetic, Safety, and Tolerability Study of PF-07265807 as Monotherapy and in Combination in Participants with Advanced or Metastatic Solid Tumors

Conditions

  • Neoplasm Metastasis

Interventions

DRUG

PF-07265807

Given 2 weeks on/1 week off

DRUG

Sasanlimab

Given SC Q3W

DRUG

Axitinib

Dosed per package label starting with 5 mg PO BID

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-24
Primary Completion
2024-11-15
Completion
2024-11-15
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Italy
  • Japan
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04458259 on ClinicalTrials.gov